ZURA Stock Summary and Trading Ideas (Zura Bio Limited - Class A | NASDAQ:ZURA)

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Zura Bio Limited - Class A trades on the NASDAQ stock market under the symbol ZURA.

As of January 23, 2026, ZURA stock price declined to $6.36 with 516,516 million shares trading.

ZURA has a beta of 1.03, meaning it tends to be more sensitive to market movements. ZURA has a correlation of 0.03 to the broad based SPY ETF.

ZURA has a market cap of $413.51 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that ZURA belongs to (by Net Assets): VXF, IWC, SBIO, AVSC.

ZURA has outperformed the market in the last year with a price return of +269.8% while the SPY ETF gained +14.2%. ZURA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +89.3% and +24.2%, respectively, while the SPY returned +2.9% and -0.7%, respectively.

ZURA support price is $5.92 and resistance is $6.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZURA shares will trade within this expected range on the day.